Valganciclovir/Vancevir manufacturer and original research information

Valganciclovir is a prescription antiviral drug with the trade name Valganciclovir. It is mainly used clinically for the treatment and prevention of cytomegalovirus (CMV) related diseases. Its indications are closely related to the patient group, especially those with low immune function. According to international guidelines and instructions, the main indications of valganciclovir include: treatment of CMV retinitis in patients with AIDS, prevention of CMV disease after organ transplantation, and treatment or prevention of other CMV-related infections caused by immunosuppression. Its mechanism of efficacy relies on being converted into ganciclovir in the body and then embedded in viral DNA to prevent viral replication and thereby control the progression of infection.

Regarding the manufacturer and original research background, the original research company of valganciclovir is the world-renowned pharmaceutical company Roche (Roche Inc.). Roche has deep experience in the research and development of antiviral drugs. The valganciclovir tablets it developed are not only an innovative breakthrough in oral dosage forms, but also solve the previous limitations of intravenous injection of ganciclovir, greatly facilitating clinical use. As the patent protection period gradually expires, generic versions have appeared in many countries and regions, such as India, Europe and some pharmaceutical companies in China. While maintaining efficacy, generic drugs have also significantly reduced patient medication costs, providing accessible options for more patients.

In clinical applications, transplantation medicine is a key area for the use of valganciclovir. Whether it is a kidney, liver or heart transplant,CMV is one of the common complications. If not prevented, CMV will not only directly damage organ function, but may also induce acute rejection and significantly reduce graft survival rate. The long-term preventive regimen of valganciclovir has been recommended by guidelines from many countries and has been proven to effectively reduce CMV infection rates and improve patient prognosis.

Reference materials:https://go.drugbank.com/drugs/DB01610